NCT07242612Completed
Bone Turnover Markers and Treatment Efficacy in Postmenopausal Osteoporosis
Determination of Selective Bone Turnover Markers and Their Association With Treatment Efficacy in Primary Postmenopausal Osteoporotic Women: A Randomized Control Trial
Source: ClinicalTrials.gov · Last updated 13 Aug 2026
Brief summary (registry, in English)
This study investigates the use of blood tests known as Bone Turnover Markers (BTMs) to quickly monitor the effectiveness of osteoporosis treatment in postmenopausal women. Osteoporosis, which weakens bones and increases fracture risk, is typically monitored using a DEXA scan to measure bone density (BMD), but this method changes slowly. BTMs may show a response to medication within just 3 to 6 months. In this randomized controlled trial, 40 postmenopausal women with osteoporosis will be assigned to receive either antiresorptive drugs (which slow bone loss) or anabolic drugs (which build new bone), along with calcium and vitamin D. The study will compare how these treatments affect BTMs and BMD over six months to determine if BTMs can serve as an early and reliable indicator of treatment success, which could be particularly useful in regions like Pakistan where access to repeated DEXA scans is limited.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 40 (actual)
- First submitted
- 17 Nov 2025
- Start date
- 1 Oct 2025
- Primary completion date
- 25 Mar 2026
- Lead sponsor
- Khyber Medical University Peshawar
- Diseases
- Osteoporosis
- NCT number
- NCT07242612
What you commit to
- Study type: Interventional
- Participants enrolled: 40
- From 1 Oct 2025 to the primary completion date, 25 Mar 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of hormone/estrogen therapy, calcitonin, oral bisphosphonates, IV ibandronate, IV Zoledronic acid, denosumab, or teriparatide within the past 18 months.
- Use of corticosteroids (short or long-term).
Other illness
- History of hyperthyroidism, hypothyroidism, liver disease, kidney disease, or tumors.
- Presence of secondary causes of osteoporosis (e.g., eating disorders, celiac disease, diabetes, hematologic disorders).
Other
- Women with multiple vertebral fractures or severe lumbar degenerative changes.
Who the study is looking for
- Postmenopausal women (at least one year since last menstrual cycle).
- Age greater than 50 years.
- Diagnosis of primary osteoporosis.
- Currently not on any anti-osteoporosis medications.
- Not taking Calcium or Vitamin D supplements.
- Volunteer to participate and provide informed consent.
Age in the registry: 50 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Northwest General Hospital Coordinator of this site? Confirm its status | Peshawar | Pakistan | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.